After PGT-SR Shows No Transferable Embryos: Questions for a Second Opinion

PGT-SR is intended for people carrying defined structural chromosome rearrangements, such as balanced translocations. A family karyotype or other confirmed genetic report guides the test. Start by verifying that the rearrangement recorded by the IVF laboratory matches the parental report and that both were interpreted by qualified professionals. The report should describe which embryos were successfully tested, what categories were assigned and whether any samples were inconclusive. “Abnormal” without detail does not tell the patient whether the laboratory detected an unbalanced rearrangement, another chromosomal finding or a technical limitation.

The number of eggs, mature eggs, fertilised embryos, blastocysts reaching biopsy and embryos with interpretable results can each differ. If only one or two embryos reached testing, the outcome has a different practical meaning than a much larger set with consistent findings. Ask the embryologist for an unbroken laboratory timeline rather than seeing only the final PGT-SR table. A biopsy analyses sampled cells and is not a guarantee of an embryo’s potential. The clinician should explain why another cycle is or is not likely to change the decision, acknowledging uncertainty.

Discuss reproductive risks, residual test uncertainty, prenatal testing options in any future pregnancy and whether testing a different family member would improve the assay. The specialist should also address how the lab labels balanced, normal, unbalanced or mosaic findings and whether transfer policies differ. Couples may wish to discuss attempting another retrieval, untested embryos in specific circumstances, donor gametes or adoption. These decisions are personal and should not be reduced to a clinic’s “success package.” Avoid signing for another retrieval before understanding which part of the pathway failed.

The costs may include further genetics review, IVF medicines, retrieval, ICSI, biopsy, laboratory analysis per embryo, cryostorage and later transfer. Ask for the no-blastocyst, biopsy-failed and no-transferable-embryo refund or cancellation rules in writing. Paying for PGT-SR does not ensure an embryo will be available to transfer. An ethical second opinion should distinguish evidence-based advice from optional add-ons that merely increase costs. It is reasonable to pause while the couple considers medical, emotional and financial limits.

The second-opinion team should first reconcile the parental karyotypes with the PGT-SR laboratory report. Ask whether embryo IDs, biopsy dates and sample tracking are internally consistent. The clinician can then separate how many eggs were collected from how many embryos reached biopsy and how many had an interpretable result. This reveals whether the main limitation was ovarian response, fertilisation, blastocyst development or chromosomal classification. A conclusion drawn only from the final “no transferable embryo” line misses these distinctions. If laboratory methods have changed since the cycle, ask whether that matters for a future attempt and what uncertainty remains. Do not discard reports simply because a cycle ended unsuccessfully.

Couples may experience pressure to pay immediately for another retrieval because “time is running out.” Age and ovarian reserve can create real time sensitivity, but the decision still requires informed consent and a discussion of limits. Ask what new information an additional cycle might provide, what alternative pathways are reasonable and which procedures are optional. Psychological counselling may help with grief and decisions about embryos, donor material or stopping treatment. The family’s reproductive goals and values deserve respect. No single PGT-SR result can measure a person’s worth or determine the only acceptable family-building path. The purpose of a review is clarity and agency, not to manufacture certainty where none exists.

Obtain both parental chromosome reports, the embryology log, embryo-by-embryo PGT-SR report and laboratory method details. Ask what the genetics lab can clarify and what question would justify retesting or another cycle. Any new clinic should reconcile identities and previous reports before proposing a new assay; generic marketing summaries are not a substitute for these records.

A useful consultation should leave you with three things: a diagnosis or clearly stated uncertainty, the next medically necessary action, and a method for sharing results with the clinician who is accountable for decisions. In discussions about PGT-SR no transferable embryos, ask whether the team has reviewed the primary reports rather than only messages or screenshots. Clarify who will provide informed consent, which procedure needs a physical examination, and what would cause the plan to change. If new tests are advised, ask when a result is expected to affect the choice between observation, medication, IUI, IVF or another route. There is no value in a test that generates a number but does not help the patient or treating doctor make a safer decision.

HomeIVF can help structure a doctor-led second-opinion conversation and coordinate specialist genetic review remotely where available. Selected home blood sampling may support preparation if medically relevant and locally offered. Embryo testing requires laboratory biopsy and specialist analysis; egg retrieval, ultrasounds and embryo transfer remain clinical procedures. Home-based support cannot change an unfavourable genetic result.

Treatment decisions are easier to evaluate when clinicians make the underlying uncertainty explicit. Ask which finding is proven, what remains a possibility and what change in care is expected from each new test or procedure. A written plan should include sensible stopping or review points, the role of a second opinion and an explanation of what will happen if the cycle cannot proceed. Avoid buying an optional technology because its name sounds more advanced.